← Eichor
Study identifier: NCT04523428 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

Condition: CLL/SLL  ·  Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

PhasePhase 2
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Fixed-duration regimens containing combinations of venetoclax with CD20 targeting agents are expected to soon become standard practice in first-line patients with chronic lymfocytic leukemia (CLL). The advantage of a fixed duration venetoclax combination as part of first-line treatment is the potential to retreat with venetoclax in patients who develop relapsed disease after a treatment free period. However, efficacy of venetoclax retreatment following a fixed duration venetoclax combination is still hypothetical as clinical data are lacking. Thus, there is an urgent need for data proving efficacy of venetoclax combinations following venetoclax treatment cessation. Testing of a novel venetoclax-containing regimen for relapsed CLL without the repeat of anti-CD20 monoclonal antibody (mAb) is a rational approach.

This description comes directly from the study's public registry record.

Talk to the study team

A. Kater  ·  +31 20 5665785  ·  a.p.kater@amsterdamumc.nl

H. Visser  ·  +31 10 7041560  ·  hovon@erasmusmc.nl

Always discuss trial participation with your own doctor first.

Locations (18)

BE-Bruxelles-STLUCBrussels, BelgiumRecruiting
BE-Leuven-UZLEUVENLeuven, BelgiumRecruiting
DK-Aarhus N-AUHAarhus, DenmarkRecruiting
NL-Den Bosch-JBZ's-Hertogenbosch, NetherlandsRecruiting
NL-Amsterdam-AMCAmsterdam, NetherlandsRecruiting
NL-Arnhem-RIJNSTATEArnhem, NetherlandsRecruiting
NL-Breda-AMPHIABreda, NetherlandsRecruiting
NL-Delft-RDGGDelft, NetherlandsRecruiting
NL-Dordrecht-ASZDordrecht, NetherlandsRecruiting
NL-Ede-ZGVEde, NetherlandsRecruiting
NL-Eindhoven-MAXIMAMCEindhoven, NetherlandsRecruiting
NL-Groningen-UMCGGroningen, NetherlandsRecruiting

+ 6 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04523428